Business Wire03.28.18
NAMSA, the world’s only medical research organization (MRO) that accelerates medical device development through integrated laboratory, clinical research and regulatory consulting services, has introduced a French language website.
The release of this online resource comes as a result of significant, increased demand for NAMSA’s medical device development services throughout France, the second largest European medical technology marketplace behind Germany, which is expected to reach 16.3 billione uros in revenue by 2020, according to GlobalData statistics.
“The introduction of NAMSA’s first-ever French language website comes on the heels of our recently launched Japanese and German websites, representing NAMSA’s dedication to serving clients within our established, yet quickly growing, global footprint,” commented Christopher Rupp, director of Global Marketing and Sales Operations, NAMSA. “This user-friendly, resource-rich website will allow French medtech developers to easily identify a proven, single source solution for expedited, cost-effective outsourced medical device development.”
Consistently recognized as a leader within the contract research organization (CRO) industry, NAMSA has a proven and established track record of delivering savings of up to 23 months and more than $17 million throughout the product development continuum. For over 50 years, NAMSA has placed a dedicated focus on the judicious use of client resources and the delivery of high-quality development services, and has assisted thousands of customers to successfully launch life-changing medical products around the world.
NAMSA is a medical research organization that accelerates medical device product development through integrated laboratory, clinical research and regulatory consulting services. Driven by regulatory expertise, NAMSA’s MRO approach plays an important role in translational research, applying a unique combination of disciplines—consulting, regulatory, preclinical, toxicology, microbiology, chemistry, clinical and quality—to move clients’ products through the development process, and continue to provide support through commercialization to post-market requirements anywhere in the world.
The release of this online resource comes as a result of significant, increased demand for NAMSA’s medical device development services throughout France, the second largest European medical technology marketplace behind Germany, which is expected to reach 16.3 billione uros in revenue by 2020, according to GlobalData statistics.
“The introduction of NAMSA’s first-ever French language website comes on the heels of our recently launched Japanese and German websites, representing NAMSA’s dedication to serving clients within our established, yet quickly growing, global footprint,” commented Christopher Rupp, director of Global Marketing and Sales Operations, NAMSA. “This user-friendly, resource-rich website will allow French medtech developers to easily identify a proven, single source solution for expedited, cost-effective outsourced medical device development.”
Consistently recognized as a leader within the contract research organization (CRO) industry, NAMSA has a proven and established track record of delivering savings of up to 23 months and more than $17 million throughout the product development continuum. For over 50 years, NAMSA has placed a dedicated focus on the judicious use of client resources and the delivery of high-quality development services, and has assisted thousands of customers to successfully launch life-changing medical products around the world.
NAMSA is a medical research organization that accelerates medical device product development through integrated laboratory, clinical research and regulatory consulting services. Driven by regulatory expertise, NAMSA’s MRO approach plays an important role in translational research, applying a unique combination of disciplines—consulting, regulatory, preclinical, toxicology, microbiology, chemistry, clinical and quality—to move clients’ products through the development process, and continue to provide support through commercialization to post-market requirements anywhere in the world.